Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.78 |
| ▸ | NPC1 | O15118 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13713486 | 0.83 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL19318495 | 0.83 | TSHR (0.58) | RAB9ANPC1SMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL22920041 | 0.82 | L3MBTL1 (0.60) | RAB9ANPC1SMN1; SMN2PKMNAMPT | |
| SCHEMBL2858634 | 0.82 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL14417064 | 0.80 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL18125241 | 0.80 | NPC1 (0.67) | RAB9ANPC1SMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL29602550 | 0.79 | RAB9A (0.65) | RAB9ANPC1PKMNAMPTLMNA | |
| SCHEMBL49506 | 0.79 | RAB9A (0.65) | RAB9ANPC1PKMNAMPTLMNA | |
| SCHEMBL12156880 | 0.79 | RAB9A (0.62) | RAB9ANPC1SMN1; SMN2TSHRPKM | |
| SCHEMBL9637653 | 0.79 | MEN1 (0.77) | RAB9ANPC1TSHRPKMNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922415-A | Novel bicyclic compounds as dual ATX/CA inhibitors | 豪夫迈·罗氏有限公司 | 2018-04-17 | — | — | CN | claimed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-11219625-B2 | Inhibitors of N-linked glycosylation and methods using same | YALE UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| CN-109071533-B | Halogenated allylamine indole and azaindole derivative inhibitors of lysyl oxidase and uses thereof | 法玛西斯有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| WO-2003048137-A1 | METABOTROPIC GLUTAMATE RECEPTOR-5 MODULATORS | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20030022883-A1 | Compounds and their use | EISAI INC. | 2003-01-30 | — | — | US | disclosed |
| US-6479483-B2 | 3,4,6-SUBSTITUTED PYRIDINE DERIVATIVES USEFUL FOR TREATING DEPRESSION AND PAIN, RESULTING FROM INFLAMMATORY CONDITIONS, SUCH AS MIGRAINE, RHEUMATOID ARTHRITIS, ASTHMA AND INFLAMATORY BOWEL DISEASE; NK1 RECEPTOR ANTAGONIST | HOFFMANN-LA ROCHE INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | BOOTH RICHARD JOHN (US) | 2002-10-24 | — | — | US | disclosed |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | BOS MICHAEL (CA) | 2002-07-11 | — | — | US | disclosed |
| WO-2002044183-A2 | BENZOAZEPINE AND BENZODIAZEPINE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| CN-1270959-A | 4-phenyl pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2000-10-25 | — | — | CN | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
| CN-1111242-A | Benzenesulfonamide derivative and process for preparing thereof | TANABE SEIYAKU CO (JP) | 1995-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022883-A1 | Compounds and their use | PARP1, PARP2, PARP3 | RAB9A 2743/4885NPC1 1117/4885SMN1; SMN2 2136/4885 |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | RAB9A 3792/4885NPC1 3838/4885SMN1; SMN2 4153/4885 |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | RAB9A 4230/4885NPC1 1708/4885SMN1; SMN2 2231/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | RAB9A 365/4885NPC1 3660/4885SMN1; SMN2 3149/4885 |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | HNMT, EHMT2, SHMT2 | RAB9A 3504/4885NPC1 1353/4885SMN1; SMN2 2190/4885 |
| US-20020156281-A1 | Amide inhibitors of microsomal triglyceride transfer protein | CETP, MTTP, LCAT | RAB9A 2995/4885NPC1 35/4885SMN1; SMN2 4738/4885 |
| US-11219625-B2 | Inhibitors of N-linked glycosylation and methods using same | ENGASE, FUT5, B3GNT2 | RAB9A 2521/4885NPC1 124/4885SMN1; SMN2 2325/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | RAB9A 2286/4885NPC1 809/4885SMN1; SMN2 3902/4885 |
| US-20020091265-A1 | 4-phenyl-pyridine derivatives | CBR1, CBR3, HCCS | RAB9A 2854/4885NPC1 680/4885SMN1; SMN2 3866/4885 |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | RAB9A 2468/4885NPC1 2894/4885SMN1; SMN2 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.